Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer—Clinical Trials Experience
Across all tumor types, we observe that the role of immunotherapy has increased rapidly. Due to a number of potential advantages, it is considered in neoadjuvant treatment of localized tumors. In neoadjuvant settings, immunotherapy addresses micrometastatic diseases at the moment of their formation....
Gespeichert in:
| Veröffentlicht in: | Cancers 2021-10, Vol.13 (20), p.5048 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 20 |
| container_start_page | 5048 |
| container_title | Cancers |
| container_volume | 13 |
| creator | Chmielewska, Izabela Stencel, Katarzyna Kalinka, Ewa Ramlau, Rodryg Krawczyk, Paweł |
| description | Across all tumor types, we observe that the role of immunotherapy has increased rapidly. Due to a number of potential advantages, it is considered in neoadjuvant treatment of localized tumors. In neoadjuvant settings, immunotherapy addresses micrometastatic diseases at the moment of their formation. However, some issues concerning neoadjuvant and adjuvant immunotherapy still has to be covered. The choice of drug and use of monotherapy or combination regimens remains unclear. The timing of surgery and preoperative evaluation of neoadjuvant immunotherapy efficacy is challenging. Although there is currently limited confirmed clinical data to support the use of immune checkpoint blockade in the neoadjuvant and adjuvant settings, there are many studies exploring this strategy in NSCLC patients. |
| doi_str_mv | 10.3390/cancers13205048 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8534159</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2584341372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-d8bb1330aed8b7dc60152c0b3bb1afcffdd60bd5ab40ddaa23c0fa60a52cc0153</originalsourceid><addsrcrecordid>eNpdkTtPwzAQxy0EogiYWSOxsAScXJ4LEop4SVUZKLN1sR3qKrGLnVR040PwCfkkGFoQ9IZ7_vTXnY6Qk4ieA5T0gqPm0roIYprSpNghBzHN4zDLymT3Tz4ix87NqTeAKM_yfTKCJCtoVKYHBCfSoJgPS9R9gFoEVz_FfdcN2vQzaXGxCpQOJkaHjx22bVBJ78aDfg6q7xU-3t6rVmnFsQ2mVmHrguvXhbRK-ukR2Wt8Rx5v4iF5urmeVnfh-OH2vroahxzKog9FUdcRAEXps1zwjEZpzGkNvo0NbxohMlqLFOuECoEYA6cNZhQ9xT0Lh-RyrbsY6k4KLnVvsWULqzq0K2ZQsf8TrWbs2SxZkUISpaUXONsIWPMySNezTjnuT0UtzeBYnBZJXgKNwaOnW-jcDFb7874prwd57KmLNcWtcc7K5neZiLKvD7KtD8InKQuRqQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2584341372</pqid></control><display><type>article</type><title>Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer—Clinical Trials Experience</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Chmielewska, Izabela ; Stencel, Katarzyna ; Kalinka, Ewa ; Ramlau, Rodryg ; Krawczyk, Paweł</creator><creatorcontrib>Chmielewska, Izabela ; Stencel, Katarzyna ; Kalinka, Ewa ; Ramlau, Rodryg ; Krawczyk, Paweł</creatorcontrib><description>Across all tumor types, we observe that the role of immunotherapy has increased rapidly. Due to a number of potential advantages, it is considered in neoadjuvant treatment of localized tumors. In neoadjuvant settings, immunotherapy addresses micrometastatic diseases at the moment of their formation. However, some issues concerning neoadjuvant and adjuvant immunotherapy still has to be covered. The choice of drug and use of monotherapy or combination regimens remains unclear. The timing of surgery and preoperative evaluation of neoadjuvant immunotherapy efficacy is challenging. Although there is currently limited confirmed clinical data to support the use of immune checkpoint blockade in the neoadjuvant and adjuvant settings, there are many studies exploring this strategy in NSCLC patients.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers13205048</identifier><identifier>PMID: 34680195</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Biomarkers ; Cancer therapies ; Chemotherapy ; Cisplatin ; Clinical trials ; Immune checkpoint ; Immunotherapy ; Lung cancer ; Metastases ; Mutation ; Non-small cell lung carcinoma ; Patients ; Review ; Small cell lung carcinoma ; Tumors</subject><ispartof>Cancers, 2021-10, Vol.13 (20), p.5048</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-d8bb1330aed8b7dc60152c0b3bb1afcffdd60bd5ab40ddaa23c0fa60a52cc0153</citedby><cites>FETCH-LOGICAL-c398t-d8bb1330aed8b7dc60152c0b3bb1afcffdd60bd5ab40ddaa23c0fa60a52cc0153</cites><orcidid>0000-0002-0948-9071 ; 0000-0003-4791-8372</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534159/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534159/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Chmielewska, Izabela</creatorcontrib><creatorcontrib>Stencel, Katarzyna</creatorcontrib><creatorcontrib>Kalinka, Ewa</creatorcontrib><creatorcontrib>Ramlau, Rodryg</creatorcontrib><creatorcontrib>Krawczyk, Paweł</creatorcontrib><title>Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer—Clinical Trials Experience</title><title>Cancers</title><description>Across all tumor types, we observe that the role of immunotherapy has increased rapidly. Due to a number of potential advantages, it is considered in neoadjuvant treatment of localized tumors. In neoadjuvant settings, immunotherapy addresses micrometastatic diseases at the moment of their formation. However, some issues concerning neoadjuvant and adjuvant immunotherapy still has to be covered. The choice of drug and use of monotherapy or combination regimens remains unclear. The timing of surgery and preoperative evaluation of neoadjuvant immunotherapy efficacy is challenging. Although there is currently limited confirmed clinical data to support the use of immune checkpoint blockade in the neoadjuvant and adjuvant settings, there are many studies exploring this strategy in NSCLC patients.</description><subject>Biomarkers</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Clinical trials</subject><subject>Immune checkpoint</subject><subject>Immunotherapy</subject><subject>Lung cancer</subject><subject>Metastases</subject><subject>Mutation</subject><subject>Non-small cell lung carcinoma</subject><subject>Patients</subject><subject>Review</subject><subject>Small cell lung carcinoma</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkTtPwzAQxy0EogiYWSOxsAScXJ4LEop4SVUZKLN1sR3qKrGLnVR040PwCfkkGFoQ9IZ7_vTXnY6Qk4ieA5T0gqPm0roIYprSpNghBzHN4zDLymT3Tz4ix87NqTeAKM_yfTKCJCtoVKYHBCfSoJgPS9R9gFoEVz_FfdcN2vQzaXGxCpQOJkaHjx22bVBJ78aDfg6q7xU-3t6rVmnFsQ2mVmHrguvXhbRK-ukR2Wt8Rx5v4iF5urmeVnfh-OH2vroahxzKog9FUdcRAEXps1zwjEZpzGkNvo0NbxohMlqLFOuECoEYA6cNZhQ9xT0Lh-RyrbsY6k4KLnVvsWULqzq0K2ZQsf8TrWbs2SxZkUISpaUXONsIWPMySNezTjnuT0UtzeBYnBZJXgKNwaOnW-jcDFb7874prwd57KmLNcWtcc7K5neZiLKvD7KtD8InKQuRqQ</recordid><startdate>20211009</startdate><enddate>20211009</enddate><creator>Chmielewska, Izabela</creator><creator>Stencel, Katarzyna</creator><creator>Kalinka, Ewa</creator><creator>Ramlau, Rodryg</creator><creator>Krawczyk, Paweł</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0948-9071</orcidid><orcidid>https://orcid.org/0000-0003-4791-8372</orcidid></search><sort><creationdate>20211009</creationdate><title>Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer—Clinical Trials Experience</title><author>Chmielewska, Izabela ; Stencel, Katarzyna ; Kalinka, Ewa ; Ramlau, Rodryg ; Krawczyk, Paweł</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-d8bb1330aed8b7dc60152c0b3bb1afcffdd60bd5ab40ddaa23c0fa60a52cc0153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biomarkers</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Clinical trials</topic><topic>Immune checkpoint</topic><topic>Immunotherapy</topic><topic>Lung cancer</topic><topic>Metastases</topic><topic>Mutation</topic><topic>Non-small cell lung carcinoma</topic><topic>Patients</topic><topic>Review</topic><topic>Small cell lung carcinoma</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chmielewska, Izabela</creatorcontrib><creatorcontrib>Stencel, Katarzyna</creatorcontrib><creatorcontrib>Kalinka, Ewa</creatorcontrib><creatorcontrib>Ramlau, Rodryg</creatorcontrib><creatorcontrib>Krawczyk, Paweł</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chmielewska, Izabela</au><au>Stencel, Katarzyna</au><au>Kalinka, Ewa</au><au>Ramlau, Rodryg</au><au>Krawczyk, Paweł</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer—Clinical Trials Experience</atitle><jtitle>Cancers</jtitle><date>2021-10-09</date><risdate>2021</risdate><volume>13</volume><issue>20</issue><spage>5048</spage><pages>5048-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Across all tumor types, we observe that the role of immunotherapy has increased rapidly. Due to a number of potential advantages, it is considered in neoadjuvant treatment of localized tumors. In neoadjuvant settings, immunotherapy addresses micrometastatic diseases at the moment of their formation. However, some issues concerning neoadjuvant and adjuvant immunotherapy still has to be covered. The choice of drug and use of monotherapy or combination regimens remains unclear. The timing of surgery and preoperative evaluation of neoadjuvant immunotherapy efficacy is challenging. Although there is currently limited confirmed clinical data to support the use of immune checkpoint blockade in the neoadjuvant and adjuvant settings, there are many studies exploring this strategy in NSCLC patients.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>34680195</pmid><doi>10.3390/cancers13205048</doi><orcidid>https://orcid.org/0000-0002-0948-9071</orcidid><orcidid>https://orcid.org/0000-0003-4791-8372</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2021-10, Vol.13 (20), p.5048 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8534159 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Biomarkers Cancer therapies Chemotherapy Cisplatin Clinical trials Immune checkpoint Immunotherapy Lung cancer Metastases Mutation Non-small cell lung carcinoma Patients Review Small cell lung carcinoma Tumors |
| title | Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer—Clinical Trials Experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T02%3A33%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neoadjuvant%20and%20Adjuvant%20Immunotherapy%20in%20Non-Small%20Cell%20Lung%20Cancer%E2%80%94Clinical%20Trials%20Experience&rft.jtitle=Cancers&rft.au=Chmielewska,%20Izabela&rft.date=2021-10-09&rft.volume=13&rft.issue=20&rft.spage=5048&rft.pages=5048-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers13205048&rft_dat=%3Cproquest_pubme%3E2584341372%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2584341372&rft_id=info:pmid/34680195&rfr_iscdi=true |